Genetic factors associated with Body Mass Index (BMI) have been widely studied over the last decade. We examined whether genetic variants previously associated with BMI in the general population are associated with cardiometabolic parameter worsening in the psychiatric population receiving psychotropic drugs, a high-risk group for metabolic disturbances. Classification And Regression Trees (CARTs) were used as a tool capable of describing hierarchical associations, to pinpoint genetic variants best predicting worsening of cardiometabolic parameters (i.e total, HDL and LDL-cholesterol, triglycerides, body mass index, waist circumference, fasting glucose, and blood pressure) following prescription of psychotropic drugs inducing weight gain in a discovery sample of 357 Caucasian patients. Significant findings were tested for replication in a second Caucasian psychiatric sample (n=140).
Association of variants in
Mehdi Gholam-Rezaee, 2 Wassim Raffoul, 3 Lee Ann Applegate, 3 Paris Jafari, 3 Franziska Gamma, 4 Armin von Gunten, 5 Philippe Conus, 6 Chin B Eap, 1,7, 
INTRODUCTION
Cardiovascular diseases constitute a major health concern associated with high morbidity and mortality. Comorbidities such as obesity, dyslipidemia, diabetes and hypertension are complex clinical conditions and major contributing risk factors for the development of cardiovascular diseases. Such medical conditions result from the interaction between numerous genetic and environmental factors (e.g. sedentary lifestyle with excessive dietary intake) (1, 2) . Genetic risk factors were actually reported to account for up to 40 to 70% of inter-individual variability for the most extensively studied obesity-related phenotype, namely the BMI (3, 4) . The largest meta-analysis of Genome-Wide Association Studies (GWAS) to date has reported 97 different loci associated with BMI in 339,224 individuals (5).
In psychiatry, patients suffering from severe mental illness have a reduced life expectancy of 10 to 25 years compared to the general population due mainly to cardiovascular diseases resulting from the psychiatric disorder and/or comorbidities, but also from the prescription of psychotropic treatments (6) . Thus, many antipsychotics, in particular atypical antipsychotics, some mood stabilizers and antidepressants induce metabolic dysfunctions by inducing weight gain (7), dyslipidemia (8) , type 2 diabetes (9-11), and/or hypertension (12) to varying degrees. For instance, clozapine and olanzapine are associated with the greatest risk for developing weight gain and other metabolic effects (7) . All of these factors result in serious morbidity such as cardiovascular diseases (13) and a decreased medication adherence. Dyslipidemia, type 2 diabetes and hypertension can develop either as a direct or collateral consequence of the use of psychotropic drugs. Although precise mechanisms underlying metabolic side effects induced by psychotropic drugs are only partially elucidated to date, the dual antagonism on serotonin and dopamine receptors was shown to stimulate appetite leading to weight gain and other long-term comorbidities (14) . Furthermore, independent antagonism actions on adrenergic and muscarinic receptors were directly related with decreasing insulin secretion and pancreatic β-cell response (15) . Over the last decade, pharmacogenetics of psychotropic-induced weight gain has been extensively studied using candidate gene approaches, in particular within dopamine and serotonin receptors (16, 17) . In addition, numerous single nucleotide polymorphisms (SNPs) within genes involved in other pathways of metabolism regulation (e.g. enzymes, receptors or transcriptional coactivators involved in leptin-melanocortin pathways, genes involved in cholesterol and/or in glucose homeostasis) were also associated with weight gain in psychiatric patients taking psychotropic drugs (18) (19) (20) (21) (22) .
A growing body of evidence suggests that obesity and psychiatric diseases share common etiological pathways, which may be illustrated by the observed synergistic influence of genes associated with obesity and with psychiatric illness on cardiometabolic parameters (23) . In addition, recent pharmacogenetic studies have shown stronger influence on obesity phenotypes of some BMI-associated genes in the psychiatric population treated with weight gain inducing psychotropic drugs compared to the general population (19) (20) (21) . Unfortunately, it is unknown to which extent the 97 variants associated with BMI in the general population are associated with other cardiometabolic phenotypes in the psychiatric population, despite that such populations are at very high risk for cardiometabolic disorders. Because cardiometabolic traits have a complex etiology, with an important variability, the aim of the present study was to determine whether population-based genetic variants related to BMI are associated with cardiometabolic phenotypes in patients from two psychiatric samples who were prescribed known weight gain inducing psychotropic drugs. The analyses were performed using methods capable of detecting hierarchical associations, in order to further refine the underlying biological mechanisms of cardiometabolic phenotypes in psychiatry.
MATERIALS AND METHODS

Psychiatric samples
A prospective cohort study is ongoing in the Lausanne Psychiatric University Hospital schizoaffective disorder; F30.0-F31.9 bipolar disorder; F32.0-F33.9 depressive disorder). Written informed consents for inclusion in the study and also for the genetic analyses were obtained from patients or their legal representatives. The study was approved by the Ethics Committee of Lausanne University Hospital. Further description of the cohort study was published elsewhere (22, 25) .
Discovery and replication samples
97 SNPs associated with BMI in a recent population-based meta-analysis (5) were tested for association with worsening of cardiometabolic variables in the discovery sample. The discovery sample consisted of 357 Caucasian patients from the abovedescribed prospective cohort study, with available clinical data for at least two periods including baseline data. Positive results (i.e. for a smaller subset of SNPs) were tested for replication in the replication sample, composed of 140 Caucasian patients from the same cohort study, with available clinical data for at least two periods of treatment but without baseline data (all patients with baseline data were already included in the discovery sample). Changes of metabolic parameters are more important at the beginning of treatment and including patients with baseline data in the discovery cohort increases the power to detect significant associations between SNPs and cardiometabolic parameters. Thereafter, only the strongest signals were confirmed using the replication sample.
SNP selection and genotyping
97 SNPs were selected according to the previously mentioned population-based metaanalysis (5). DNA from blood samples of psychiatric patients was extracted using the (27) .
RegulomeDB annotation
The Regulome database (http://www.regulomedb.org/) was used to assess the functional activity of significant SNPs (28) . This database defines SNPs with known and/or predicted regulatory elements located in intergenic regions of the human genome. Known and predicted regulatory elements include regions of DNAase hypersensitivity, binding sites of transcription factors and promoter regions biochemically characterized to the regulation of transcription. Sources for these data include public datasets from GEO, the ENCODE project and the published literature.
Statistical analyses
Statistical analyses were performed using Stata 12 (StataCorp, College Station TX, USA) and R version 3.1.1. Hardy-Weinberg equilibrium (HWE) testing was performed for the 97 SNPs using Pearson's chi-squared test. SNPs for which p-value was higher than 0.05 were considered in HWE.
Classification And Regression Trees (CARTs) are used to segregate SNPs that best predict the worsening of cardiometabolic variables during different periods of the psychotropic treatment. CARTs can be grown using the so called Recursive Partitioning and Regression Trees algorithms (29) . These algorithms are implemented in a few softwares including R environment for statistical programming and data analysis (rpart library). At each node, the split rule is applied which is based on the Generalized Gini index, the split can be performed if number of observations exceeds a certain threshold (the threshold in this study was 20) . Pruning can be used in function of the desired complexity of the tree. Complexity of the constructed tree at each node is represented by the so called Complexity Parameter which is equivalent to the decrease in relative error rate of the tree if the split at each that node survives after the tree is pruned.
CARTs were first performed on the discovery sample to identify clinical (age, sex, smoking status) and genetic (97 SNPs) variables best predicting worsening of cardiometabolic features during the psychotropic treatment (i.e. increase of BMI, waist circumference (WC), total cholesterol (TC), fasting triglycerides (TG), low-density lipoprotein (LDL), fasting glucose (GLC), systolic blood pressure (SBP) and/or of diastolic blood pressure (DBP), and/or decrease of high-density lipoprotein (HDL)). Of note, patients receiving lipid-lowering, antidiabetic and/or antihypertensive drugs were excluded from TC, TG, LDL, HDL analyses, GLC analyses and SBP and DBP analyses, respectively (S1 Table) . In order to determine short-and long-term risk factors associated with metabolic disturbances, CARTs were performed at several periods of treatment (i.e. from ≥10 to <45 days; from ≥45 to <135 days and from ≥135 to <535 days of psychotropic treatment). Variables in the first three layers of the CART tree structure Significant associations were then tested in the replication sample using the same model. GAMMs were fitted using the mgcv package of R, in which parameter uncertainties (confidence intervals and p-values) were computed using bootstrap (1000 replicates or 10000 replicates whenever possible with replacement, performed on patient level). P-values of two-sided models ≤ 0.05 were considered as statistically significant. 
RESULTS
Characteristics of psychiatric samples S2
Association of SNPs with cardiometabolic phenotypes in psychiatric samples
In the discovery sample, 18 out of the 57 different SNPs were significantly associated with at least one cardiometabolic phenotype using multiple linear models adjusted for age, sex, BMI and smoking status (p<0.05) ( Table 2) . Two out of the 18 SNPs were significantly replicated in the replication sample, with SH2B1 rs3888190C>A and RABEP1 rs1000940A>G being significantly associated with LDL levels (p=0.007) and FG levels (p=0.03), respectively ( 
Association of SH2B1 rs3888190C>A with LDL levels in psychiatric samples
In the discovery sample, rs3888190C>A was significantly associated with LDL levels, Fig.b) , the overall proportion of patients with abnormal LDL levels was lower for rs3888190-CC carriers (47%) compared to rs3888190-A allele carriers (53%; p=0.03).
Association of RABEP1 rs1000940A>G with fasting glucose levels in psychiatric samples
In the discovery sample, rs1000940A>G was significantly associated with fasting Although neither SH2B1 rs3888190C>A nor RABEP1 rs1000940A>G were detected as having a possible influence on BMI in CART analyses, both SNPs were tested for association with BMI in the discovery psychiatric sample. No significant association was observed between these two SNPs and BMI in the discovery sample (data not shown).
DISCUSSION
The present study aimed to explore whether SNPs previously associated with BMI and other cardiometabolic variables in the general population (5) are associated with the worsening of cardiometabolic phenotypes in a psychiatric population receiving weight gain inducing psychotropic treatments. In particular, we aimed to better refine underlying mechanisms linking and/or discerning genetics of BMI with regard to other cardiometabolic comorbidities in the psychiatric population, considering that the prevalence of metabolic syndrome has been reported twice as high in this population compared to the general population (31).
Our preliminary exploration using CART analyses highlighted and ranked 57 different
SNPs that predicted the best metabolic parameter worsening during psychotropic treatment in the discovery sample. In the latter sample, 18 SNPs were significantly associated with cardiometabolic phenotypes but the remaining 39 SNPs were not, probably due to adjustment for covariates (i.e. age, sex, BMI and/or smoking status) in GAMM analyses, which was not performed in exploratory CART analyses. Out of the 18
SNPs, SH2B1 rs3888190C>A and RABEP1 rs1000940A>G were replicated in the second psychiatric replication sample. The 16 remaining SNPs were not replicated, possibly due to the lower sample size of the latter sample compared to the discovery sample and the probable minor influence of these SNPs on cardiometabolic variables.
Thus, SH2B1 rs3888190C>A and RABEP1 rs1000940A>G were significantly associated with low-density lipoprotein levels and fasting glucose levels, respectively, in two separate psychiatric samples. As recent population-based studies did not observe such associations (5, 32) this is, to our knowledge, the first genetic study that suggested an influence of SH2B1 rs3888190C>A on LDL as well as of RABEP1 rs1000940A>G on fasting glucose levels. These different results between general and psychiatric populations may in part be explained by a lower risk towards dyslipidemia and diabetes in population-based individuals compared to psychiatric patients receiving psychotropic treatments (33) . Of note, since a 1% reduction in LDL-cholesterol on average was shown to reduce risks for hard coronary heart disease events by approximately 1% in short-term controlled trials (34), the observed difference of LDL levels between SH2B1 rs3888190C>A genotypes appears clinically relevant.
In order to differentiate SNPs according to their short-and/or long-term influence on metabolic features, CART analyses were conducted after several distinct periods of psychotropic treatment. Both SH2B1 rs3888190C>A and RABEP1 rs1000940A>G appeared to exert an influence already before the current psychotropic treatment initiation, which may be explained by the fact that most patients were not drug naïve when starting the current psychotropic treatment. Further studies are required to characterize how these genetic variants influence these two metabolic parameters in drug naïve patients. It is of particular interest to note that our results within this observational psychiatric sample reflect real clinical conditions.
The LDL-increasing allele of SH2B1 rs3888190C>A in the psychiatric population, Several limitations of the present study should be considered. Firstly, this study was limited to Caucasian patients and results cannot be generalized to other ethnicities.
Secondly, the functional activity of SH2B1 rs3888190C>A and of RABEP1 rs1000940A>G could not be assessed in the psychiatric population. Third, association with SH2B1 rs3888190C>A did not survive to multiple testing correction. However, the present results were replicated in a second psychiatric sample and functional analyses strengthen the validity of our data. Moreover, our results within this observational psychiatric sample reflect real clinical conditions.
In conclusion, this is the first genetic study to identify an association between SH2B1 rs3888190C>A and LDL levels as well as between RABEP1 rs1000940A>G and glucose levels. Our results are in agreement with the previously reported roles of the many probable affected genes in metabolism and provide new insight into the implication of these genes in the human regulation of cholesterol and glucose, in particular in the psychiatric population receiving psychotropic drugs. Finally, the considerable regulatory function of these genetic regions emphasizes the probable involvement of many regulatory genes and supports further studies to better understand mechanisms underlying the metabolic regulation of cholesterol and glucose, in particular in the psychiatric population.
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Among SNPs from CART analyses (in Table 1 ), 18 SNPs were significantly associated with cardiometabolic variables in the discovery sample using GAMM models, with SNPs considered as dominant or recessive according to CART results. 
